Cognition Therapeutics Files 8-K

Ticker: CGTX · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateJan 28, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing

TL;DR

Cognition Therapeutics filed an 8-K on Jan 28, 2025. Details TBD.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on January 28, 2025, reporting other events and financial statements/exhibits. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates Cognition Therapeutics is providing updates to the SEC, which could relate to significant corporate events or financial disclosures.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate negative or positive financial implications evident in the provided text.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Cognition Therapeutics, Inc. in this 8-K filing?

The provided text for the 8-K filing does not specify the details of the 'Other Events' being reported.

What is the date of the earliest event reported in this Form 8-K?

The date of the earliest event reported is January 28, 2025.

In which state was Cognition Therapeutics, Inc. incorporated?

Cognition Therapeutics, Inc. was incorporated in Delaware.

What is the SEC file number for Cognition Therapeutics, Inc.?

The SEC file number for Cognition Therapeutics, Inc. is 001-40886.

What is the business address listed for Cognition Therapeutics, Inc.?

The business address listed is 2500 Westchester Avenue Purchase, NY 10577.

Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2025-01-28 16:41:34

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. Attached as Exhibit 99.1 is a presentation that the Company may use from time to time in presentations or discussions with investors, analysts, and other parties.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Corporate presentation of Cognition Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: January 28, 2025 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing